Thursday, November 15, 2012
Courtesy of The Journal Record
OKLAHOMA CITY – Cytovance Biologics Inc. has an agreement with Selexys Pharmaceuticals Corp. to produce the SelG1 monoclonal antibody for a clinical study.
A recent agreement with a pharmaceutical company and the securing of financing will allow Selexys to advance the SelG1 program through a large phase II clinical study in patients with sickle cell disease.
SelG1 will be manufactured at Cytovance’s 44,000-square-foot production facility in Oklahoma City.
“Cytovance continues to be an integral part of our efforts at Selexys and has played a key role in the advancement of our clinical programs,” said Scott Rollins, president and CEO of Selexys.
Cytovance collaborated with Selexys Pharmaceuticals in 2010 to develop and manufacture its Anti-PSGL-1 therapeutic agent, a monoclonal antibody developed for treatment of inflammation associated with Crohn’s disease.
Click here to read the article at the Journal Record website.
